Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBIT (2016 - 2025)

China Pharma Holdings' EBIT history spans 16 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, EBIT changed 0.35% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$3.2 million, up 29.41%, while the annual FY2025 figure was -$3.2 million, 29.41% up from the prior year.
  • EBIT reached -$1.2 million in Q4 2025 per CPHI's latest filing, down from -$628145.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.4 million in Q4 2022 to a low of -$1.4 million in Q2 2024.
  • Average EBIT over 5 years is -$521061.7, with a median of -$733245.0 recorded in 2021.
  • The largest YoY upside for EBIT was 79.18% in 2021 against a maximum downside of 1104.13% in 2021.
  • A 5-year view of EBIT shows it stood at $1.4 million in 2021, then increased by 3.25% to $1.4 million in 2022, then crashed by 43.28% to $797625.0 in 2023, then plummeted by 249.95% to -$1.2 million in 2024, then decreased by 0.35% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's EBIT are -$1.2 million (Q4 2025), -$628145.0 (Q3 2025), and -$652120.0 (Q2 2025).